Chemotherapy combinated with ADSCs genetically engineered to express human carboxylesterase-2, can overcome drug resistance and exhibit survival benefits in ovarian cancer with intraperitoneal metastasis [43]. The gene discussed is CES2; the disease is ovarian cancer.